ClinicalTrials.gg
RecruitingNCT06687434Updated May 20, 2025

Carb Counting vs. Simplified Qualitative Meal-Size Estimation

An interventional study of accurate carb counting and Simplified qualitative meal size estimation in Type 1 Diabetes Mellitus, sponsored by Rabin Medical Center. Recruiting at 1 site in Israel. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Rabin Medical Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.

Planned enrollment
4th of 38
120 · median 30
Started
2024
with 2 others
No phase
31 of 42
5 open now
Registered
39th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the 4th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 31 with no phase, and was the 39th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, or all of them as a file.
02

Study summary

The goal of this study is to compare qualitative meal-size estimation to accurate carb counting in adolescents with Type One Diabetes using all available AID (Automated Insulin Delivery) systems. We will compare glucose control parameters and patient related outcome measures between the groups. 120 children and adolescents with type 1 Diabetes who begin using AID system will be randomly assigned to one of two groups: simplified qualitative meal size estimation or accurate carb counting. The study will last 6 months, with an additional optional follow up points at 12 and 24 months.

In the first visit all patients will receive nutrition guidance from the dietitian. In the accurate carb counting group, participants will use precise carb counting to manage their meals. In the simplified qualitative meal-size estimation group, participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment. During the study, the dietitian will evaluate the insulin-to-carb ratio and meal estimation at least once in the first two weeks.

Follow-up visits will be scheduled at 4-6 weeks, 3, and 6 months after the study's initiation. At each visit participants will upload their data from their AID systems. Evaluation of their diabetes control will be made and an assessment regarding the carbohydrates calculation method. Digital questionnaires assessing diabetes distress, disordered eating behaviors, dietary regimen, and eating patterns will be provided at the beginning of the study and after 6 months, with an additional optional follow-up points that will be held at 12 and 24 months after the study's initiation.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Automated insulin delivery system
  • carb counting
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. T1D- diagnosed
  2. Age 6-18 years
  3. Treated with insulin (multiple daily injections or pump) and intending to initiate treatment with AID systems

Exclusion criteria

Exclusion Criteria:

  1. Non-T1D
  2. Unstable medical conditions (other than diabetes) that may impact weight or diabetes management (as severe psychiatric disorders, various syndromes)
  3. Use of medications that may impact weight or diabetes management (as use of for an extended period of time. use of GLP-1)
  4. Inability to understand the information, material and questionnaires of the study -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Accurate carb counting

    Participants will use precise carb counting to manage their meals

    Behavioral: accurate carb counting

  • Experimental
    Simplified qualitative meal-size estimation

    Participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian assessment.

    Behavioral: Simplified qualitative meal size estimation

Interventions

  • Behavioralaccurate carb counting

    Participants will use precise carb counting to manage their meals

  • BehavioralSimplified qualitative meal size estimation

    participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.

06

What researchers measure

Primary outcomes

  1. Percentage of time in target range (70-18mg/dl)

    Time frame: Screening, after 4-6 weeks, after 3 months and after 6 months

  2. Hemoglobin A1C

    Time frame: Screening, after 4-6 weeks, after 3 months and after 6 months

  3. Percentage Continuous glucose monitoting usage

    Time frame: Screening, after 4-6 weeks, after 3 months and after 6 months

  4. Number of Episodes of severe hypoglycemia

    Time frame: Screening, after 4-6 weeks, after 3 months and after 6 months

  5. Number of episodes of Diabetic Ketoacidosis

    Time frame: Screening, after 4-6 weeks, after 3 months and after 6 months

Secondary outcomes

  1. Total daily insulin dose

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  2. basal insulin dose

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  3. Number of manual boluses per day

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  4. Number of announced meals per day

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  5. Daily carbohydrates input

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  6. Percentage of automated insulin delivery use

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  7. Number of automated insulin delivery exits per week

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  8. Percentage of automated boluses

    Time frame: at screening, after 4-6 weeks, after 3 months and after 6 months.

  9. Score of Diabetes distress according to questionnaire

    Time frame: At screening and after 6 months

  10. Score of Disordered eating behaviors according to quesiotnnaire

    Time frame: At screening and after 6 months

  11. Score of Dietary regimen according to questionnaire

    Time frame: At screening and after 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2027, 34 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 34 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Nov 13, 2024
StartActual
Dec 15, 2024
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 15, 2027
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06687434
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Dec 15, 2024
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
May 20, 2025

Study contacts

Tal Oron, DR.
Contact
talo@clalit.org.il
972-544-290-296
Michal Gilon Keren, Phd
Contact
michalgk@clalit.org.il
972-524-311292

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion